Natera, Inc. (NTRA): Price and Financial Metrics
NTRA Price/Volume Stats
Current price | $91.46 | 52-week high | $96.24 |
Prev. close | $90.46 | 52-week low | $36.90 |
Day low | $89.20 | Volume | 971,200 |
Day high | $92.42 | Avg. volume | 1,526,880 |
50-day MA | $77.92 | Dividend yield | N/A |
200-day MA | $58.05 | Market Cap | 11.04B |
NTRA Stock Price Chart Interactive Chart >
NTRA POWR Grades
- Growth is the dimension where NTRA ranks best; there it ranks ahead of 67.84% of US stocks.
- NTRA's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
- NTRA ranks lowest in Momentum; there it ranks in the 7th percentile.
NTRA Stock Summary
- NTRA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 152.85 -- higher than 81.16% of US-listed equities with positive expected earnings growth.
- With a price/sales ratio of 7.2, NATERA INC has a higher such ratio than 85.45% of stocks in our set.
- As for revenue growth, note that NTRA's revenue has grown 27.41% over the past 12 months; that beats the revenue growth of 83.19% of US companies in our set.
- Stocks that are quantitatively similar to NTRA, based on their financial statements, market capitalization, and price volatility, are CLPT, BLZE, DYAI, ASAN, and NVCR.
- NTRA's SEC filings can be seen here. And to visit NATERA INC's official web site, go to www.natera.com.
NTRA Valuation Summary
- In comparison to the median Healthcare stock, NTRA's EV/EBIT ratio is 202.74% lower, now standing at -15.
- NTRA's price/earnings ratio has moved up 198.6 over the prior 103 months.
Below are key valuation metrics over time for NTRA.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
NTRA | 2023-12-29 | 7.6 | 9.6 | -15.1 | -15.0 |
NTRA | 2023-12-28 | 7.5 | 9.5 | -14.9 | -14.8 |
NTRA | 2023-12-27 | 7.4 | 9.4 | -14.7 | -14.6 |
NTRA | 2023-12-26 | 7.4 | 9.4 | -14.7 | -14.6 |
NTRA | 2023-12-22 | 7.4 | 9.3 | -14.6 | -14.5 |
NTRA | 2023-12-21 | 7.3 | 9.2 | -14.5 | -14.4 |
NTRA Growth Metrics
- The 3 year revenue growth rate now stands at 154.56%.
- Its 5 year revenue growth rate is now at 63.07%.
- Its 4 year net income to common stockholders growth rate is now at -2.49%.
The table below shows NTRA's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 775.998 | -449.11 | -545.79 |
2022-06-30 | 723.477 | -437.923 | -575.583 |
2022-03-31 | 667.303 | -397.637 | -546.458 |
2021-12-31 | 625.486 | -335.236 | -471.716 |
2021-09-30 | 564.836 | -309.802 | -407.564 |
2021-06-30 | 504.863 | -251.871 | -314.614 |
NTRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NTRA has a Quality Grade of D, ranking ahead of 16.91% of graded US stocks.
- NTRA's asset turnover comes in at 0.553 -- ranking 46th of 81 Healthcare stocks.
- CHE, USPH, and VCYT are the stocks whose asset turnover ratios are most correlated with NTRA.
The table below shows NTRA's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.553 | 0.496 | -0.316 |
2021-03-31 | 0.510 | 0.498 | -0.272 |
2020-12-31 | 0.490 | 0.479 | -0.286 |
2020-09-30 | 0.509 | 0.480 | -0.277 |
2020-06-30 | 0.609 | 0.472 | -0.279 |
2020-03-31 | 0.692 | 0.462 | -0.273 |
NTRA Price Target
For more insight on analysts targets of NTRA, see our NTRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $150.11 | Average Broker Recommendation | 1.35 (Strong Buy) |
Natera, Inc. (NTRA) Company Bio
Natera Inc. is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The company was founded in 2003 and is based in San Carlos, California.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR TestAUSTIN, Texas, December 28, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the federal District Court for the Middle District of North Carolina has issued a preliminary injunction, effective immediately, enjoining the RaDaR assay from NeoGenomics Labs, Inc. ("NeoGenomics"). |
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
While Natera (NASDAQ:NTRA) shareholders have made 323% in 5 years, increasing losses might now be front of mind as stock sheds 4.7% this weekLong term investing can be life changing when you buy and hold the truly great businesses. And highest quality... |
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNAAUSTIN, Texas, December 21, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter (MTM/mL) against mean variant allele frequency (mVAF) for measuring circulating tumor DNA (ctDNA), using Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test. The full study can be found here. |
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera PatentsAUSTIN, Texas, December 11, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that the United States District Court for the District of Delaware has issued an order denying CareDx’s motion for summary judgment on two Natera patents in the infringement lawsuit filed by Natera against CareDx. |
NTRA Price Returns
1-mo | 19.48% |
3-mo | 46.01% |
6-mo | 106.69% |
1-year | 68.56% |
3-year | -5.86% |
5-year | 343.55% |
YTD | 46.01% |
2023 | 55.94% |
2022 | -56.99% |
2021 | -6.16% |
2020 | 195.40% |
2019 | 141.33% |
Continue Researching NTRA
Here are a few links from around the web to help you further your research on Natera Inc's stock as an investment opportunity:Natera Inc (NTRA) Stock Price | Nasdaq
Natera Inc (NTRA) Stock Quote, History and News - Yahoo Finance
Natera Inc (NTRA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...